S. Stegemann, “Improved Therapeutic Entities Derived from Known Generics as an Unexplored Source of Innovative Drug Product,” European Journal of Pharmaceutical Science, Vol. 44, No. 4, 2011, pp. 447-454.
http://dx.doi.org/10.1016/j.ejps.2011.09.012

has been cited by the following article:

• TITLE: Strategy of Innovation’s Management in the Pharmaceutical Industry Holds Intellectual Property

  AUTHORS: Cássia Rita Pereira da Veiga, Claudimar Pereira da Veiga, Jansen Maia Del Corso, Anderson Catapan

  KEYWORDS: Management of Innovation; Intellectual Property; Patent; Pharmaceutical Industry

  JOURNAL NAME: American Journal of Industrial and Business Management, Vol.3 No.6, October 24, 2013

  ABSTRACT: In the management of innovation, intellectual property rights assume the primary role. In this sense, this paper aims to describe, with examples, the various strategies used by the pharmaceutical industry in the preservation of their legitimate rights of the intellectual property system. This is an exploratory study by using documentary research and longitudinal time. Even with the difference in laws between countries, the pharmaceutical anti-competitive practices gain more space in the global economy. For patents become political tools that foster innovation and diffusion of knowledge, it is suggested that revisions in the legislation, homogeneous international regulation and supervision of health authorities ensure quality of product and control of pharmaceutical marketing. This work also addresses political and social considerations on the subject while exploring some suggestions of ideal patent system.